Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
161Tb-NYM032 in mCRPC
NCT06827080Phase 2Not yet recruiting
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of 161Tb-NYM032 in metastatic castration-resistant prostate cancer (mCRPC). Primary endpoints: Prostate Specific Antigen and 68Ga-NYM032 Positron Emission Tomography/Computed Tomography. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
161Tb-NYM032
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06827080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827080.